Loading
Immunotherapy can trigger dangerous attacks on the gut, lungs or heart. Use blood, gut bacteria and genetic markers to spot who is at risk and act early.
Immune-related adverse events cause treatment discontinuation and death, and their management is reactive. Autoantibody profiles, HLA types, microbiome composition, baseline cytokines and early T-cell clonal expansion are each associated with specific toxicities in retrospective series. The proposal is a prospective biomarker cohort across checkpoint inhibitor indications to derive and validate a toxicity risk model, followed by trials of pre-emptive strategies (early steroid-sparing agents, microbiome modulation, intensified monitoring) in high-risk patients.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Immune-related adverse events (irAEs), Toxicity and quality of life are undervalued.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Toxicity and quality of life are undervalued.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Toxicity and quality of life are undervalued.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Toxicity and quality of life are undervalued.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Toxicity and quality of life are undervalued.
Shares Immune-related adverse events (irAEs), No one can predict who responds to immunotherapy, Toxicity and quality of life are undervalued, Immune checkpoint inhibitors.
Shares Immune-related adverse events (irAEs), Ipilimumab, Toxicity and quality of life are undervalued, Pembrolizumab.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Toxicity and quality of life are undervalued.